Su Y, Subedee A, Bloushtain-Qimron N, et al. Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. Cell Rep. 2015;11(10):1549-63. doi:10.1016/j.celrep.2015.05.011
Kim KH, Kim W, Howard TP, et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015;21(12):1491-6. doi:10.1038/nm.3968
Gannon HS, Kaplan N, Tsherniak A, et al. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016;14(2):207-15. doi:10.1158/1541-7786.MCR-15-0321
Pomerantz MM, Li F, Takeda DY, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015;47(11):1346-51. doi:10.1038/ng.3419
Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41(7):843-8. doi:10.1038/ng.392
Duan Z, Bradner JE, Greenberg E, et al. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res. 2006;12(22):6844-52. doi:10.1158/1078-0432.CCR-06-1330
Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105(25):8713-7. doi:10.1073/pnas.0803379105
Nijhawan D, Zack TI, Ren Y, et al. Cancer vulnerabilities unveiled by genomic loss. Cell. 2012;150(4):842-54. doi:10.1016/j.cell.2012.07.023
Yuan Y, Tang AJ, Castoreno AB, et al. Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells. Cell Death Dis. 2013;4:e690. doi:10.1038/cddis.2013.191
Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301-5. doi:10.1126/science.1244851